<DOC>
	<DOCNO>NCT02671058</DOCNO>
	<brief_summary>This study open label , single dose , randomize , 2 way ( 2 period ) crossover study healthy adult subject single study center .</brief_summary>
	<brief_title>Pharmacokinetics Bioavailability Hydrocortisone Acetate Suppositories</brief_title>
	<detailed_description>This study open label , single dose , randomize , 2 way ( 2 period ) crossover study healthy adult subject single study center . Screening evaluation occur Day 28 Day 2 subject confine clinical research unit ( CRU ) Day 1 Day 2 treatment period . The treatment period separate least 7 day washout period . Subjects meet study enrollment criterion randomly assign 1 2 sequence ( AB BA ) Day 1 Treatment Period 1 receive either reference product ( A ) treatment product ( B ) study</detailed_description>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>1 . Healthy male female subject 18 45 year age , inclusive , time Screening . 2 . Female subject must : Of non childbearing potential ( surgically sterile [ hysterectomy , oophorectomy bilateral tubal ligation ] postmenopausal &gt; 1 year follicle stimulate hormone [ FSH ] &gt; 40 U/L ) , Non pregnant , non lactate female childbearing potential able willing undertake adequate measure prevent pregnancy include use medically acceptable form birth control subject partner ( hormonal birth control , abstinence , diaphragm spermicide , condom spermicide , intrauterine device , vasectomy surgical sterilization ) Screening End Study . 3 . Male subject must able willing undertake adequate measure prevent pregnancy throughout study include use medically acceptable form birth control subject partner ( hormonal birth control , abstinence , diaphragm spermicide , condom spermicide , intrauterine device , vasectomy , surgical sterilization post menopausal partner ) Screening End Study . 4 . Body mass index ( BMI ) ≥ 18.0 ≤ 30.0 kg/m2 time Screening . 5 . Subject willing able provide inform consent . 6 . Subject willing able confine CRU adhere study lifestyle restriction . 1 . History clinically significant illness surgery determine Principal Investigator designee , within 5 year prior first IMP administration . 2 . History evidence clinically significant pathology include neurological , cardiovascular , endocrine , pulmonary , gastrointestinal , renal , hepatic , hematological , immunological , psychiatric metabolic disorder ( ) determine Principal Investigator designee . 3 . Any significant rectal pathology , opinion Principal Investigator designee , would contraindication ( warn ) hydrocortisone acetate suppository hydrocortisone retention enema include rectal obstruction , abscess , perforation , active fungal infection ( ) and/or bacterial infection ( ) . 4 . Subject anal sex , cosmetic anal bleaching perianal waxing within 30 day prior first IMP administration . 5 . History constipation , diarrhea frequent bowel movement per day within 30 day prior first IMP administration . 6 . Any clinically significant abnormality ( include clinically significant laboratory test result [ ] ) find Screening febrile illness infection within 7 day prior Screening Admission ( Day 1 Treatment Period 1 ) CRU . 7 . Positive test hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( anti HCV ) , human immunodeficiency virus ( HIV ) antibody Screening . 8 . Clinically significant electrocardiogram ( ECG ) abnormality Screening , determine Principal Investigator designee . 9 . Positive pregnancy test ( female ) Screening Admission ( Day 1 Treatment Periods 1 2 ) CRU . 10 . Subject history alcohol abuse significant regular alcohol use within 1 year prior Screening , define exceed 14 unit alcohol per week , , 1 unit = 12 ounce beer , 5 ounce wine 1.5 ounce hard liquor . 11 . Positive serum alcohol test Screening Admission ( Day 1 Treatment Periods 1 2 ) CRU . 12 . History regular tobacco use use nicotine contain product control tobacco use within past 6 month prior Screening . 13 . Positive urine drug test ( include amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates phencyclidine ) Screening Admission ( Day 1 Treatment Periods 1 2 ) CRU . 14 . Use counter ( OTC ) medication ( include oral natural health product , vitamin herbal supplement ) within 7 day prior first IMP administration End Study use prescription medication within 14 day prior first IMP administration End Study . By exception , acetaminophen &lt; 1000 mg per day , hormonal contraception hormonal replacement therapy permit . 15 . Known allergy history hypersensitivity hydrocortisone inert component either formulation test . 16 . Participation another clinical study within 60 day prior first IMP administration . Participation consider last dose IMP another study . 17 . Donation loss blood ( &gt; 100 mL ) either whole blood plasma within 60 day prior first IMP administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bioavailability</keyword>
</DOC>